Home >> Public Health >> Pharmaceuticals >> Food & Beverage >>

Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013

Published: Apr-2013 | Format: PDF | Global Markets Direct | Number of pages: 104 | Code: MRS - 827

Global Markets Directs, 'Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma). Systemic Sclerosis (Scleroderma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Scope


A snapshot of the global therapeutic scenario for Systemic Sclerosis (Scleroderma).
A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma).
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Systemic Sclerosis (Scleroderma) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Systemic Sclerosis (Scleroderma) 10
Systemic Sclerosis (Scleroderma) Therapeutics under Development by Companies 12
Systemic Sclerosis (Scleroderma) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Systemic Sclerosis (Scleroderma) Therapeutics Products under Development by Companies 20
Systemic Sclerosis (Scleroderma) Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Systemic Sclerosis (Scleroderma) Therapeutics Development 23
Bristol-Myers Squibb Company 23
Genzyme Corporation 24
F. Hoffmann-La Roche Ltd. 25
Sanofi-Aventis 26
GlaxoSmithKline plc 27
MedImmune LLC 28
BioLineRx, Ltd. 29
FibroGen, Inc. 30
Celgene Corporation 31
Active Biotech AB 32
Accentia Biopharmaceuticals, Inc. 33
Digna Biotech, S.L. 34
Mondobiotech Holding AG 35
Angion Biomedica Corp. 36
Daval International Ltd. 37
Systemic Sclerosis (Scleroderma) Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
belimumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
paquinimod - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
tocilizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
P-17 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
disitertide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
disitertide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
anifrolumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MEDI-551 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
pomalidomide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
bosentan - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
imatinib mesylate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Aimspro - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BMS-986202 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SAR-100842 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sildenafil citrate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AM-095 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
fresolimumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
imatinib mesylate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CC-220 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ANG-3070 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
DasKloster 0112-01 + DasKloster 022801 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DasKloster-050101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ABK-16 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TCR Inhibitors - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
acALY18 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
1D-11 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
EDP-34 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Systemic Sclerosis (Scleroderma) Therapeutics Drug Profile Updates 81
Systemic Sclerosis (Scleroderma) Therapeutics Discontinued Products 94
Systemic Sclerosis (Scleroderma) Therapeutics - Dormant Products 95
Systemic Sclerosis (Scleroderma) Product Development Milestones 97
Featured News & Press Releases 97
Oct 10, 2011: Daval Announces Positive Phase II Results For AIMSPRO As Monotherapy In Diffuse Scleroderma 97
Jun 23, 2011: FDA Grants Orphan Drug Status For Accentia's Revimmune Therapy In Systemic Sclerosis And Hemolytic Anemia 98
Feb 20, 2011: Daval International Announces Completion Of Phase II Trial Evaluating Safety And Efficacy Of AIMSPRO 99
Nov 18, 2010: COMP Recommends Orphan Drug Status To Active Biotech's 57-57 Project 99
May 06, 2010: Anti-Fibrotic Data From Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published In The British Journal Of Pharmacology 100
Apr 22, 2010: Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension 100
Jan 12, 2010: Epratuzumab Receives U.S. Patent - Lupus Foundation Of America, Inc. 101
Nov 05, 2009: AIMSPRO receives US orphan-drug designation for ALS 101
Feb 23, 2009: GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd 101
Jun 27, 2008: GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg 102

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104


List of Tables

Number of Products Under Development for Systemic Sclerosis (Scleroderma), H1 2013 10
Products under Development for Systemic Sclerosis (Scleroderma) Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Bristol-Myers Squibb Company, H1 2013 23
Genzyme Corporation, H1 2013 24
F. Hoffmann-La Roche Ltd., H1 2013 25
Sanofi-Aventis, H1 2013 26
GlaxoSmithKline plc, H1 2013 27
MedImmune LLC, H1 2013 28
BioLineRx, Ltd., H1 2013 29
FibroGen, Inc., H1 2013 30
Celgene Corporation, H1 2013 31
Active Biotech AB, H1 2013 32
Accentia Biopharmaceuticals, Inc., H1 2013 33
Digna Biotech, S.L., H1 2013 34
Mondobiotech Holding AG, H1 2013 35
Angion Biomedica Corp., H1 2013 36
Daval International Ltd., H1 2013 37
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 43
Systemic Sclerosis (Scleroderma) Therapeutics Drug Profile Updates 81
Systemic Sclerosis (Scleroderma) Therapeutics Discontinued Products 94
Systemic Sclerosis (Scleroderma) Therapeutics Dormant Products 95
Systemic Sclerosis (Scleroderma) Therapeutics Dormant Products (Contd..1) 96 

List of Figures


Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2013 10
Products under Development for Systemic Sclerosis (Scleroderma) Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Route of Administration, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Molecule Type, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 43 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing